A case report of FOLFOX treatment for primary duodenal carcinoma with multiple liver metastases

Yasuhiro Fujiwara; Yoshio Naomoto; Shunsuke Tanabe; Kazufumi Sakurama; Kazuhiro Noma; Toshio Nishikawa; Takayuki Motoki; Munenori Takaoka; Yasuhiro Shirakawa; Tomoki Yamatsuji; Junji Matsuoka; Noriaki Tanaka

A case report of FOLFOX treatment for primary duodenal carcinoma with multiple liver metastases

Yasuhiro Fujiwara, Yoshio Naomoto, Shunsuke Tanabe, Kazufumi Sakurama, Kazuhiro Noma, Toshio Nishikawa, Takayuki Motoki, Munenori Takaoka, Yasuhiro Shirakawa, Tomoki Yamatsuji, Junji Matsuoka, Noriaki Tanaka

Research output: Contribution to journal › Article › peer-review

Abstract

We report a case of a woman in her sixties having primary duodenal carcinoma with multiple liver metastases who was treated with oxaliplatin in combination with infusional 5-fluorouracil/Leucovorin (FOLFOX regimen). After completing 2 courses of the chemotherapy, computed tomography showed a partial response without any severe adverse events. Now at 8 months, the PR stage has been maintained. So far, no standard therapeutic strategy for metastatic duodenal carcinoma has been developed. However, we suggest a FOLFOX regimen can be highly effective as a safe approach for continuously maintaining the quality of life of patients with this rare type of cancer.

Original language	English
Pages (from-to)	655-657
Number of pages	3
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	36
Issue number	4
Publication status	Published - Apr 2009

Keywords

FOLFOX
Liver metastasis
Primary duodenal carcinoma

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{a42b1c639a30455191e786d2c1faf4e0,

title = "A case report of FOLFOX treatment for primary duodenal carcinoma with multiple liver metastases",

abstract = "We report a case of a woman in her sixties having primary duodenal carcinoma with multiple liver metastases who was treated with oxaliplatin in combination with infusional 5-fluorouracil/Leucovorin (FOLFOX regimen). After completing 2 courses of the chemotherapy, computed tomography showed a partial response without any severe adverse events. Now at 8 months, the PR stage has been maintained. So far, no standard therapeutic strategy for metastatic duodenal carcinoma has been developed. However, we suggest a FOLFOX regimen can be highly effective as a safe approach for continuously maintaining the quality of life of patients with this rare type of cancer.",

keywords = "FOLFOX, Liver metastasis, Primary duodenal carcinoma",

author = "Yasuhiro Fujiwara and Yoshio Naomoto and Shunsuke Tanabe and Kazufumi Sakurama and Kazuhiro Noma and Toshio Nishikawa and Takayuki Motoki and Munenori Takaoka and Yasuhiro Shirakawa and Tomoki Yamatsuji and Junji Matsuoka and Noriaki Tanaka",

year = "2009",

month = apr,

language = "English",

volume = "36",

pages = "655--657",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "4",

}

TY - JOUR

T1 - A case report of FOLFOX treatment for primary duodenal carcinoma with multiple liver metastases

AU - Fujiwara, Yasuhiro

AU - Naomoto, Yoshio

AU - Tanabe, Shunsuke

AU - Sakurama, Kazufumi

AU - Noma, Kazuhiro

AU - Nishikawa, Toshio

AU - Motoki, Takayuki

AU - Takaoka, Munenori

AU - Shirakawa, Yasuhiro

AU - Yamatsuji, Tomoki

AU - Matsuoka, Junji

AU - Tanaka, Noriaki

PY - 2009/4

Y1 - 2009/4

N2 - We report a case of a woman in her sixties having primary duodenal carcinoma with multiple liver metastases who was treated with oxaliplatin in combination with infusional 5-fluorouracil/Leucovorin (FOLFOX regimen). After completing 2 courses of the chemotherapy, computed tomography showed a partial response without any severe adverse events. Now at 8 months, the PR stage has been maintained. So far, no standard therapeutic strategy for metastatic duodenal carcinoma has been developed. However, we suggest a FOLFOX regimen can be highly effective as a safe approach for continuously maintaining the quality of life of patients with this rare type of cancer.

AB - We report a case of a woman in her sixties having primary duodenal carcinoma with multiple liver metastases who was treated with oxaliplatin in combination with infusional 5-fluorouracil/Leucovorin (FOLFOX regimen). After completing 2 courses of the chemotherapy, computed tomography showed a partial response without any severe adverse events. Now at 8 months, the PR stage has been maintained. So far, no standard therapeutic strategy for metastatic duodenal carcinoma has been developed. However, we suggest a FOLFOX regimen can be highly effective as a safe approach for continuously maintaining the quality of life of patients with this rare type of cancer.

KW - FOLFOX

KW - Liver metastasis

KW - Primary duodenal carcinoma

UR - http://www.scopus.com/inward/record.url?scp=79959844802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959844802&partnerID=8YFLogxK

M3 - Article

C2 - 19381042

AN - SCOPUS:79959844802

SN - 0385-0684

VL - 36

SP - 655

EP - 657

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 4

ER -

A case report of FOLFOX treatment for primary duodenal carcinoma with multiple liver metastases

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this